New developments in the management of chronic lymphocytic leukemia: role of ofatumumab

Ofatumumab is one of the three anti-CD20 monoclonal antibodies currently available for the treatment of chronic lymphocytic leukemia (CLL). The US Food and Drug Administration (FDA) approved the use of ofatumumab in patients with CLL refractory to fludarabine and alemtuzumab in 2009, and the Europea...

Descripción completa

Detalles Bibliográficos
Autores principales: Laurenti, Luca, Innocenti, Idanna, Autore, Francesco, Sica, Simona, Efremov, Dimitar G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725726/
https://www.ncbi.nlm.nih.gov/pubmed/26855591
http://dx.doi.org/10.2147/OTT.S72845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725726/
https://www.ncbi.nlm.nih.gov/pubmed/26855591
http://dx.doi.org/10.2147/OTT.S72845

Ejemplares similares